CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

Photo: Rob Acket/EMA

Pfizer's medicine candidate tanezumab is the only new medicine that the European Committee for Medicinal Products for Human Use (CMPH) is refusing to approve. This is clear from the highlights publicized after the committee's September meeting.

Tanezumab, also known as Raylumis, was intended as a treatment for pains associated with osteoarthritis, a form of arthritis, and is currently being evaluated by the US Food and Drug Administration (FDA), however in March of this year, an FDA advisory committee also voted against a recommendation of approval – 19 people against one.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs